Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT Latent Tuberculosis study
ISRCTN04379941Phase 4Completed
- Sponsor
- University College London
- Start
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of isoniazid + rifampicin, rifapentine and isoniazid in latent tuberculosis infection (LTBI), sponsored by University College London. Primary endpoints: Completion of treatment regimen and Cost effectiveness. Started May 2014; status: completed.
02
Drugs
isoniazid + rifampicinrifapentineisoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ISRCTN04379941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN04379941.